Amplification of the genes encoding MET and epidermal growth factor receptor 2 (HER2/ERBB2) is frequently observed in recurrent tumors of NSCLC patients who received EGFR-TKIs as a first-line treatment [58]. Here, ERBB2 is linked to non-small cell lung carcinoma.